NCT00688259

Brief Summary

This is a study comparing the benefits of two types of individual psychotherapy (cognitive-behavioral therapy for psychosis and supportive therapy) in symptomatic Veteran outpatients diagnosed with schizophrenia or schizoaffective disorder. Treatment lasted approximately 6 months, with outcome data on symptoms, functioning, and distress levels collected at baseline, post-treatment, and 6 months post -treatment follow-up.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
122

participants targeted

Target at P75+ for not_applicable schizophrenia

Timeline
Completed

Started Apr 2009

Longer than P75 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 28, 2008

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 2, 2008

Completed
10 months until next milestone

Study Start

First participant enrolled

April 1, 2009

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2014

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
3 years until next milestone

Results Posted

Study results publicly available

December 14, 2017

Completed
Last Updated

April 9, 2025

Status Verified

March 1, 2025

Enrollment Period

5.4 years

First QC Date

May 28, 2008

Results QC Date

December 19, 2016

Last Update Submit

March 24, 2025

Conditions

Keywords

clinical trialspsychotherapy

Outcome Measures

Primary Outcomes (4)

  • Changes in Positive Schizophrenia Symptoms

    Mean positive symptoms Interview rating on the Brief Psychiatric Rating Scale (Ventura, Lukoff. Nuechterlein. Liberman, Green, \& Shaner, 1993), with range of 1-7 and higher scores indicating greater symptoms Ventura, J. Lukoff D, Nuechterlein KH, Liberman RP, Green M, Shaner A: Appendix 1: Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0) scales, anchor points and administration manual. International Journal of Methods in Psychiatric Research 1993; 3:227-243

    Pre-treatment to end of treatment, approximately 6 months post-randomization

  • Changes in Positive Schizophrenia Symptoms

    Mean positive symptoms Interview rating on the Brief Psychiatric Rating Scale (Ventura, Lukoff. Nuechterlein. Liberman, Green, \& Shaner, 1993), with range of 1-7 and higher scores indicating greater symptoms Ventura, J. Lukoff D, Nuechterlein KH, Liberman RP, Green M, Shaner A: Appendix 1: Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0) scales, anchor points and administration manual. International Journal of Methods in Psychiatric Research 1993; 3:227-243

    Pre-treatment to follow-up, approximately 6 months post end-of-treatment

  • Changes in Global Social Functioning

    Interview rating of overall adaptive functioning rated on a 1-7 scale on the Social Adjust Scale II (Schooler, Hogarty, Weissman:, 1979) with low scores indicating better functioning Schooler N, Hogarty G,\& Weissman M, (1979). Social Adjustment Scale (SAS) II, in Resource Materials for Community Mental Health Program Evaluators. Edited by Hargreaves W, Attkisson C, Sorenson J. Rockville MD, US Department of Health, Education, and Welfare, 1979, pp 290-303)

    Pre-treatment to end of treatment, approximately 6 months post-randomization

  • Changes in Global Social Functioning

    Interview rating of overall adaptive functioning rated on a 1-7 scale on the Social Adjust Scale II (Schooler N, Hogarty G, Weissman M:, 1979) with low scores indicating better functioning Schooler N, Hogarty G,\& Weissman M, (1979). Social Adjustment Scale (SAS) II, in Resource Materials for Community Mental Health Program Evaluators. Edited by Hargreaves W, Attkisson C, Sorenson J. Rockville MD, US Department of Health, Education, and Welfare, 1979, pp 290-303)

    Pre-treatment to follow-up, approximately 6 months post end-of-treatment

Secondary Outcomes (2)

  • Changes in Distress From Schizophrenia Symptoms

    Pre-treatment to end-of-treatment, approximately 6 months post-randomization

  • Changes in Distress From Schizophrenia Symptoms

    Pre-treatment to follow-up, approximately 6 months post end-of-treatment

Study Arms (2)

Cognitive Behavioral Therapy for Psychosis (CBTp)

EXPERIMENTAL

approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.

Behavioral: Cognitive Behavioral Therapy for Psychosis (CBTp)

Supportive Therapy (ST)

ACTIVE COMPARATOR

approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns

Behavioral: Supportive Therapy (ST)

Interventions

approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery

Supportive Therapy (ST)

approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery

Cognitive Behavioral Therapy for Psychosis (CBTp)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • outpatients with schizophrenia or schizoaffective disorder in proximity to the West Los Angeles VAMC
  • at least one month since last hospitalization
  • stable antipsychotic medication with persisting psychotic symptoms with at least minimal distress
  • competent to sign informed consent.

You may not qualify if:

  • in other individual psychotherapy
  • presence of organic brain disease
  • mental retardation
  • illness that would prohibit regular attendance in therapy
  • substance dependence diagnosis in the past 6 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

West Los Angeles, California, 90073, United States

Location

MeSH Terms

Conditions

SchizophreniaPsychotic Disorders

Interventions

Palliative CareCognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Patient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Results Point of Contact

Title
Shirley M. Glynn, Ph.D.
Organization
VA Greater Los Angeles Healthcare System at West Los Angeles

Study Officials

  • Shirley M. Glynn, PhD

    VA Greater Los Angeles Healthcare System, West Los Angeles, CA

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 28, 2008

First Posted

June 2, 2008

Study Start

April 1, 2009

Primary Completion

September 1, 2014

Study Completion

January 1, 2015

Last Updated

April 9, 2025

Results First Posted

December 14, 2017

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

De-identified data on major outcomes can be shared. Investigators can contact PI.

Locations